RESTART C0168Z05 Rheumatoid Arthritis Study

A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).

The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition to methotrexate.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Biological: Infliximab

Detailed Description

This is a Phase 4, multi center, open-label, assessor blinded, switch study of infliximab in patients with active rheumatoid arthritis who are receiving methotrexate and are having an inadequate response to their current treatment with etanercept or adalimumab. The last dose of etanercept must have been at least 1 week but not more than 2 weeks prior to the first infliximab study infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to the first infliximab study infusion. The study will be conducted for 30 weeks and will include 200 patients. All eligible patients will receive 3 mg/kg infliximab infusions (drug given into a vein) at weeks 0, 2, and 6 and every 8 weeks thereafter, if they achieve a European League Against Rheumatism (EULAR) response on their current dose of infliximab. Patients who do not achieve a EULAR response will increase their dose from 3mg/kg to 5 mg/kg at week 14. Patients who do not achieve a EULAR response at week 22 will increase from either 3 mg/kg to 5 mg/kg or from 5mg/kg to 7 mg/kg. The last study infusion will take place at week 22. The last study visit for effectiveness evaluations will take place at week 26. A week 30 follow-up visit will be performed for adverse events and tuberculosis evaluations, health economics assessments, and review of concomitant medications. All patients who end the study early will be required to complete all assessments. Patients will receive 3 mg/kg infliximab infusions at weeks 0, 2, and 6. If patients achieve European League Against Rheumatism (EULAR) response, they will remain on their current dose. Patients who do not demonstrate a EULAR response will increase their infliximab dose from 3 mg/kg to 5 mg/kg at week 14. At week 22, patients will also increase their infliximab dose from 3 mg/kg to 5mg/kg or from 5 mg/kg to 7mg/kg if they do not demonstrate a EULAR response.

• Study Type: Interventional
• Enrollment (Actual): 203
• Phase: Phase 4

Contacts and Locations

Study Locations

• Austria
  • Graz-Eggenberg, Austria
  • Wien, Austria
• Canada
  • Hamilton Ontario, Canada
  • British Columbia
    • Vancouver, British Columbia, Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada
  • Newfoundland and Labrador
    • St. John'S, Newfoundland and Labrador, Canada
  • Ontario
    • Toronto, Ontario, Canada
• Finland
  • Helsinki, Finland
• France
  • Bordeaux Cedex, France
  • Limoges, France
  • Montivilliers, France
  • Orleans, France
• Germany
  • Frankfurt, Germany
  • Holdenfelde, Germany
  • Leipzig, Germany
  • Muenchen, Germany
  • München, Germany
  • Ratingen, Germany
• Israel
  • Ashkelon, Israel
  • Beer Yaakov, Israel
  • Haifa, Israel
  • Kfar Saba, Israel
  • Ramat Gan, Israel
  • Rehovot, Israel
  • Tel-Aviv, Israel
• Netherlands
  • Alkmaar, Netherlands
• Spain
  • Madrid, Spain
  • Oviedo, Spain
  • Santiago De Compostela, Spain
• United Kingdom
  • Leeds, United Kingdom
  • London, United Kingdom
  • Wigan, United Kingdom
• United States
  • Alabama
    • Huntsville, Alabama, United States
  • Arizona
    • Paradise Valley, Arizona, United States
    • Tucson, Arizona, United States
  • California
    • Santa Monica, California, United States
  • Connecticut
    • Bridgeport, Connecticut, United States
  • Delaware
    • Lewes, Delaware, United States
  • Florida
    • Boca Raton, Florida, United States
    • Palm Harbor, Florida, United States
    • Tamarac, Florida, United States
    • Vero Beach, Florida, United States
  • Georgia
    • Atlanta, Georgia, United States
  • Illinois
    • Moline, Illinois, United States
    • Springfield, Illinois, United States
  • Kentucky
    • Lexington, Kentucky, United States
  • Maryland
    • Wheaton, Maryland, United States
  • Michigan
    • Saint Clair Shores, Michigan, United States
  • Minnesota
    • Eagan, Minnesota, United States
  • Missouri
    • Saint Louis, Missouri, United States
    • Springfield, Missouri, United States
  • New Jersey
    • Berkeley Heights, New Jersey, United States
    • Freehold, New Jersey, United States
  • New York
    • Albany, New York, United States
    • Syracuse, New York, United States
  • North Carolina
    • Chapel Hill, North Carolina, United States
  • Ohio
    • Columbus, Ohio, United States
    • Mayfield, Ohio, United States
    • Middleburg Heights, Ohio, United States
  • Oklahoma
    • Tulsa, Oklahoma, United States
  • Pennsylvania
    • Allentown, Pennsylvania, United States
    • Duncansville, Pennsylvania, United States
    • Wexford, Pennsylvania, United States
  • South Carolina
    • Charleston, South Carolina, United States
    • Greenville, South Carolina, United States
  • Tennessee
    • Jackson, Tennessee, United States
    • Nashville, Tennessee, United States
  • Texas
    • Amarillo, Texas, United States
    • Dallas, Texas, United States
    • Fort Worth, Texas, United States
    • Houston, Texas, United States
    • Mesquite, Texas, United States
    • Temple, Texas, United States
    • Tyler, Texas, United States
  • Virginia
    • Burke, Virginia, United States
    • Reston, Virginia, United States
  • Washington
    • Seattle, Washington, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have rheumatoid arthritis
• Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
• Patients must have inadequate disease response to etanercept or adalimumab
• Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.

Exclusion Criteria:

• Patients who have a history of latent or active TB
• Have inflammatory disease other than rheumatoid arthritis
• Have had a chronic or recurrent infectious disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: 001; Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response	Biological: Infliximab; 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10	Percent of patients who achieved EULAR response at Week 10. EULAR response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999). At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.	Week 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase	Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase	Week 26
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26	Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26	Week 26
Change From Baseline in Physical Function (HAQ)	Change from baseline in physical function (HAQ) at Week 10. HAQ assesses the degree of difficulty a person has in accomplishing tasks. A lower HAQ score indicates less difficulty. Change from baseline is computed as Week 10 value minus baseline value. A negative value in change from baseline indicates an improvement.	Week 10
Change From Baseline in Physical Function (HAQ)	Change from baseline in physical function (HAQ) at Week 26. HAQ assesses the degree of difficulty a person has in accomplishing tasks. A lower HAQ score indicates less difficulty. Change from baseline is computed as Week 26 value minus baseline value. A negative value in change from baseline indicates an improvement.	Week 26
Percent of Patients Who Achieved ACR20 at Week 10	Percent of patients who achieved ACR20 at Week 10. A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.	Week 10
Percent of Patients Who Achieved ACR20 at Weeks 26.	Percent of patients who achieved ACR20 at Weeks 26. A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.	Week 26

Collaborators and Investigators

• Sponsor: Centocor Ortho Biotech Services, L.L.C.
• Collaborators: Schering-Plough

Publications and helpful links

General Publications

• Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Curr Med Res Opin. 2014 Nov;30(11):2139-49. doi: 10.1185/03007995.2014.942416. Epub 2014 Jul 30.

Study record dates

Study Major Dates

• Study Start: July 1, 2008
• Primary Completion (Actual): January 1, 2010
• Study Completion (Actual): June 1, 2010

Study Registration Dates

• First Submitted: July 10, 2008
• First Submitted That Met QC Criteria: July 11, 2008
• First Posted (Estimate): July 14, 2008

Study Record Updates

• Last Update Posted (Estimate): September 12, 2013
• Last Update Submitted That Met QC Criteria: August 29, 2013
• Last Verified: August 1, 2013

More Information

Terms related to this study

• Keywords: rheumatoid arthritis; adalimumab; infliximab; etanercept; enbrel; remicade; Centocor; humira; restart; swollen joints; tender joints.
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Antirheumatic Agents; Gastrointestinal Agents; Dermatologic Agents; Infliximab
• Other Study ID Numbers: CR013879; C0168Z05 (Other Identifier: Centocor Ortho Biotech Services, L.L.C.)